Skip to main content
. 2018 Apr 9;67(9):1395–1402. doi: 10.1093/cid/ciy295

Figure 1.

Figure 1.

Unadjusted Kaplan-Meier estimates of relapse-free survival stratified by recipient cytomegalovirus (CMV) serostatus at the time of transplantation (A), receipt of antilymphocyte therapy (ALT) within 1 year prior to the completion of CMV treatment (B), and peak viral load (VL) (C). P values refer to log-rank test results (n = 170).